Drug Profile
Research programme: thrombin inhibitors - Santhera Pharmaceuticals
Alternative Names: GRA 184314; Thrombin inhibitors research programme - Santhera PharmaceuticalsLatest Information Update: 12 Mar 2008
Price :
$50
*
At a glance
- Originator Santhera Pharmaceuticals
- Class
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 12 Mar 2008 Discontinued - Preclinical for Thrombosis in Germany (unspecified route)
- 13 Sep 2004 MyoContract has merged with Graffinity Pharmaceuticals to form Santhera Pharmaceuticals
- 29 Mar 2004 This programme is available for licensing worldwide (http://www.graffinity.com)